GLP-1 Weight Loss Medications: Ozempic vs. Wegovy vs. Mounjaro Prices

GLP-1 receptor agonists — and the newer dual GIP/GLP-1 agents — are the most in-demand medications of the decade, used for type 2 diabetes and chronic weight management. They are also among the most expensive, and unlike statins or blood-pressure pills, none has a generic. This guide lays out what each really costs in 2026 and the legitimate ways to pay less.

Prices below are brand cash references from our catalog, cross-checked against the Medicare Part D spending dashboard. Approved uses trace to FDA DailyMed labeling.

The drugs and what they're approved for

• Semaglutide — sold as Ozempic (type 2 diabetes) and Wegovy (weight management). Same molecule, different labels and doses.
• Tirzepatide — a dual GIP/GLP-1 agonist sold as Mounjaro (diabetes) and Zepbound (weight).
• Dulaglutide — sold as Trulicity (diabetes).

Price comparison (monthly brand cash)

See live prices on the drug pages for Ozempic, Wegovy, Mounjaro, Zepbound, and Trulicity.

Why there are no generics yet

These are patent-protected molecules; no FDA-approved generic exists in 2026. During recent FDA-declared shortages, compounding pharmacies were temporarily allowed to prepare copies, but those exemptions ended for tirzepatide and semaglutide, so most legitimate compounding has wound down. Products still advertised far below brand pricing deserve real scrutiny — verify licensure and sourcing.

The cheapest legitimate paths

• Insurance coverage if you qualify — usually the lowest out-of-pocket when the drug is on formulary.
• Manufacturer copay cards for commercially insured patients (Novo Nordisk, Lilly).
• Manufacturer direct self-pay programs for single-dose vials, which have listed below brand pen pricing.
• Patient-assistance programs for uninsured, low-income patients — see our PAP guide.

Diabetes vs. weight-loss coverage

One of the biggest cost drivers for these drugs is not the sticker price but whether insurance covers your specific use. Plans are far more likely to cover a GLP-1 prescribed for type 2 diabetes — Ozempic, Mounjaro, or Trulicity — than the same molecule branded for weight management, such as Wegovy or Zepbound. Coverage for obesity treatment has been expanding but remains inconsistent across commercial plans, and traditional Medicare has historically excluded drugs used solely for weight loss. Check your plan's formulary and any prior-authorization requirements before assuming a price.

If your plan does not cover the weight-management indication, the manufacturer's self-pay vial programs and copay cards become the main levers. These change periodically, so verify current terms directly with the manufacturer rather than relying on a number you saw months ago.

Why these drugs are hard to price shop

Unlike generics, where comparing pharmacies can cut the price by hundreds of percent, brand-only GLP-1s have far less pharmacy-to-pharmacy variation because there is no generic competition and the manufacturer sets a high list price. That does not make comparison useless — cash prices still differ somewhat between pharmacies and coupon networks — but the largest savings come from coverage, manufacturer programs, and, for diabetes patients, sometimes choosing an equally effective but cheaper class such as an SGLT2 inhibitor when clinically appropriate. That is a conversation for your prescriber, weighing cost against the specific cardiovascular and kidney benefits each drug carries.

What drives the monthly cost besides the list price

Two patients on the same GLP-1 can pay wildly different amounts, and the reason is rarely the pharmacy shelf price. The biggest factors are whether the drug is on your plan's formulary, whether it requires prior authorization, and whether you qualify for a manufacturer copay card. A commercially insured patient with a copay card can sometimes pay a small fixed amount, while an uninsured patient faces the full brand cash price unless a self-pay vial program applies. Dose also matters: these drugs are titrated upward over weeks, and the maintenance dose can carry a different price than the starter dose, so the number you pay in month one may not be the number you pay in month six.

Because of this, the single most useful thing you can do before starting a GLP-1 is call your plan and ask three questions: is my specific drug and indication covered, is prior authorization required, and what is my expected copay at each dose. Pair that with the manufacturer's current program terms and you will have a realistic annual estimate rather than a sticker-price guess.

The bottom line on GLP-1 cost

GLP-1 and GIP/GLP-1 drugs are effective but expensive, and with no generics in 2026 the levers that work for other drug classes — generic substitution, pharmacy price shopping — matter less here. The savings that do exist come from coverage, manufacturer copay cards, self-pay vial programs, and, for uninsured low-income patients, assistance programs. Verify current terms directly with the manufacturer, be skeptical of anything sold far below brand pricing, and, for diabetes, discuss with your prescriber whether a cheaper class could meet your needs. That combination gives you a realistic path to the lowest legitimate price.

How BetterBuyRx helps

BetterBuyRx shows verified brand cash prices for each GLP-1 across pharmacies and links to the manufacturer's official program on the drug's save-on page when one exists. Because no one can pay to change our ranking, we never steer you toward a paid "deal" we cannot verify. Start with Ozempic or Mounjaro, or see our type 2 diabetes cost guide.